Institutional Investor (August 5)
Series A and B is the “inflection point…. where institutional capital typically expects clarity; clinical data, market readiness, and a signal that someone else has de-risked the science. But in women’s health, those signals often do not arrive. Not because the companies aren’t progressing but because the validation layers that used to feed the pipeline e.g. public grants, translational studies, pilot programs have eroded.” Because validation doesn’t arrive, “promising science stalls, not because of bad data, but because no one wants to be first.”
Tags: Clarity, Clinical data, De-risked, Inflection point, Institutional capital, Market readiness, Pilot programs, Promising, Public grants, Science, Series A and B, Signals, Stalls, Validation, Women’s health
